ASH 2021 Update
As part of our continued coverage of CAR-T at major international congresses, we have published a series of articles reporting on a few selected sessions from ASH 2021. We hope […]
ASH2021
Relapsed or Refractory Large B-Cell Lymphoma and the TRANSFORM study
TRANSFORM is a global, randomized, phase III study comparing the efficacy and safety of standard of care against liso-cel in patients with relapsed or refractory large b-cell lymphoma
Multiple Myeloma and the CARTITUDE-5 Protocol Presented at ASH
CARTITUDE-5 will assess the efficacy ciltacabtagene autoleucel in patients with newly diagnosed multiple myeloma
Follicular Lymphoma & the ELARA Study
ELARA is a single-arm global Phase II trial in which patients with refractory or relapsed follicular lymphoma are treated with tisagenlecleucel
High-Risk Large B-Cell Lymphoma and the ZUMA-12 study
ZUMA-12 is a single-arm phase II trial in which 42 patients received axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma